Many patients suffer from lung infl ammatory disorders including asthma, bronchitis and chronic obstructive pulmonary disorders (COPD). Several classes of drugs including bronchodilators, antitussives, steroids and leukotriene (LT) receptor antagonists have been used to treat these disorders. However, these drugs sometimes do not provide fundamental care, even though the major symptoms are alleviated (Jeffery, 2001) . Thus, new effective drugs with novel action mechanism(s) are needed to treat lung infl ammatory disorders. In this regard, natural products may be applied safely for treating human lung infl ammation and bronchitis.
INTRODUCTION

Abstract
twining shrub that has long been used to treat urinary disorders, fevers, and headache (Shougakukan, 1985) . Additionally, the whole plant of L. japonica, which is widely distributed widely in China and Korea, has frequently been used as an anti-infl ammatory agent, especially for the treatment of respiratory tract infl ammation (Lee et al., 1998) . Recently, it was also reported that highly purifi ed fraction showed potent antiinfl ammatory and analgesic activities (Ryu et al., 2010) . It has previously been reported that a 1:1 (w/w) mixture (BL) of the ethylacetate fraction from the root barks of B. papyrifera and the 70% aqueous ethanol extract from the whole plants of L. japonica exerted signifi cant and considerable anti-infl ammatory activity in vitro and in vivo (Jin et al., 2010) . BL exerted anti-infl ammatory activity against λ-carrageenan-induced paw edema and arachidonic acid-induced ear edema. Moreover, BL also showed analgesic activity. The cellular mechanisms of these anti-infl ammatory activities of BL include 5-lipoxygenase (5-LOX) inhibition and inhibition of proinfl ammatory enzyme induction such as inducible nitric oxide synthase (iNOS).
In the present study, inhibitory effects of BL against experimental lung infl ammation and bronchitis were examined to establish its potential for use as a new therapeutic agent against
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MATERIALS AND METHODS
Chemicals
2-Amino-5,6-dihydro-6-methyl-4H-1,3-thiazine hydrochloride (AMT) was purchased from Tocris Cookson Ltd. (UK). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), indomethacin, prednisolone, λ-carrageenan (CGN) and LPS (Escherichia coli 0127:B8) were purchased from Sigma Chem. (St. Louis, MO). Zileuton (5-LOX inhibitor) and montelukast (LT receptor antagonist) were purchased from Tocris Bioscience and Hwail Pharm. Co., Ltd. DMEM and other cell culture reagents including FBS were products of Gibco BRL (Grand Island, NY). Protein assay kit was purchased from Bio-Rad Lab. (Hercules, CA).
Animals
Male Sprague-Dawley (SD) rats (4 weeks old, specifi c pathogen-free) were obtained from Orient-Bio Ltd. (Korea). Animals were fed with standard lab. chow and water ad libitum. The animals were maintained in an animal facility (KNU) at [20] [21] [22] o C under 40-60% relative humidity and a 12 h/12 h (light/dark) cycle for at least 7 days prior to the experiment. The experimental design using the animals was approved by the local committee for animal experimentation, KNU (KIA-CUC-09-0012). In addition, the ethical guidelines described in the KFDA Guide for the Care and Use of Laboratory Animals were followed throughout the experiments.
Plant materials
B. papyrifera collected in southern China were obtained from Songlim Pharm. Co., Ltd. (Seoul, Korea) and the plant materials were authenticated by one of the authors, Dr. K. H. Son (Andong National University, Korea) and a voucher specimen was deposited in Andong National University. The dried root barks of B. papyrifera were chopped and extracted with ethanol. The ethanol extract was partitioned with ethylacetate and water. The ethylacetate fraction was then dried under vacuum and this dried fraction was used to prepare BL as below. The fi nal yield of this ethylacetate fraction in one typical extraction and fractionation procedure was 7.77% (w/w). The major constituents, papayrifl avonol A and broussochalcone A, were isolated according to the previously published procedures (Son et al., 2001) . For determination of the contents of major constituents, HPLC analysis was carried out. Alliance VWD separation module (Waters) and Inertsil ODS4 column (4.6×150 mm, 5 μm) were employed using the mobile phase of tetrahydrofuran:water, pH 3.0 (47:53). The fl ow rate was 0.6 ml/min and the peaks were detected at UV 390 nm. From the HPLC analysis, papyrifl avonol A and broussochalcone A were found to be 1.35% and 2.58% (w/w), respectively as shown in L. japonica cultivated in southern China was purchased from Songlim Pharm. Co., Ltd. and this plant material was authenticated by Dr. K. H. Son and a voucher specimen was deposited in Andong National University. The dried whole plant was then chopped and extracted with 70% aqueous ethanol. The ethanol extract was then dried under vacuum and this dried extract was used to prepare BL. The yield of the ethanol extract in one typical extraction procedure was 9.74% (w/w). The major constituents, loganin and sweroside, were isolated as previously described (Kawai et al., 1988) . HPLC analysis using the mobile phase of acetonitrile:water, pH 3.0 (13:87) was performed. The fl ow rate was 0.6 ml/min and the peaks were detected at UV 239 nm. In this extract, loganin and sweroside were found to be 4.19% and 3.30%, respectively. BL is a (1:1, w/w) mixture of the ethylacetate fraction of B. papyrifera and the ethanol extract of L. japonica and used throughout this study.
MH-S cell culture and measurement of nitric oxide (NO), TNF-α and IL-6
MH-S cells, a mouse alveolar macrophage cell line, obtained from American type culture collection (ATCC, Rockville, VA) were cultured with DMEM supplemented with 10% FBS and 1% antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) in a 5% CO 2 atmosphere at 37 o C. The cells were activated with lipopolysaccharide (LPS) as previously described (Chi et al., 2001a) . Briefl y, cells were plated in 96-well plates (2×10 5 cells/well). After pre-incubation for 2 h, test compounds and LPS (1 mg/ml) were added and incubated for 24 h unless otherwise specifi ed. Media was collected and NO, TNF-α and IL-6 concentrations were determined. To assess NO production, the stable conversion product of NO, nitrite (NO 2 − ), was measured using Griess reagent and the optical density was determined at 550 nm. The concentrations of TNF-α and IL-6 were measured using ELISA kit (Assay Design Inc.) according to the manufacturer's recommendation. The cell viability was checked using an MTT bioassay as previously described (Mossman, 1983 ). At all concentrations tested, BL and AMT did not show cytotoxic effect on MH-S cells.
Western blot analysis
To measure the protein level of inducible NO synthase (iNOS), Western blotting technique was used (Chi et al., 2001a) . MH-S cells were cultured in 6-well plates (5×10 6 cells/ well) in the presence or absence of LPS (1 μg/ml) with/without test compounds for 16-20 h. After cell homogenates were prepared, the supernatant was obtained by centrifugation at 15,000 g for 30 min. Using Tris-glycine gels (8%), electrophoresis was carried out and bands were blotted to PVDF membranes. The membranes were incubated with iNOS antibody (N32030, Transduction Lab.) and the bands were visualized by chemiluminescent reagent (Amersham, UK).
CGN-induced pleurisy
According to the procedure of Schrier et al. (1990) , 0.2 ml of 1% CGN solution in sterile saline was injected intrapleurally to rats. The test compounds were orally administered 1 h prior CGN injection. The animals were sacrifi ced 5 or 24 h after CGN injection. The chest was opened by lateral incision. DMEM (3 ml) with 10% FCS was injected into pleural cavity and pleural fl uid was aspirated using Pasteur pipette. This washing procedure was repeated again and exudates were combined. After the volumes of pleural exudates were recorded, cell pellets were obtained by centrifugation at 200 g for 5 min. Total cell numbers were counted after RBCs were lysed with hemolytic solution (0.85% NH 4 Cl, 0.1 M Hepes).
Bronchitis induced by LPS instillation
For inducing bronchitis, the modifi ed method of Starcher and Williams (1989) was employed. For intratracheal instillation, rats were anesthetized by tribromoethanol and LPS (E. coli 0127:B8, 2 mg/ml saline) was instilled directly to lung (100 μl/rat), using a microsprayer (Intratracheal aerosolizer, PennCentury, Inc., USA). Rats were maintained in up-right position at least for 5 min. Sixteen hours later after LPS instillation, the animals were sacrifi ced and bronchoalveolar lavage fl uid (BALF) was collected via intratracheal cannulation after 200 μl infusion of saline. BALF collected were approximately 150 μl/ rat. For histology and other biochemical analysis, lungs were excised. Test compounds including BL were administered one hour prior to LPS instillation. For measuring proinfl ammatory cytokine concentration, reverse transcription-polymerase chain reaction (RT-PCR) analysis was carried out. In brief, total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) from lung tissue and cDNA was synthesized by Superscript II reverse transcriptase with oligo (dT) primer (Invitrogen). The forward and reverse primers used for PCR amplifi cation of IL-1β and GAPDH from the lung of rats were as follows: IL-1β forward, 5'-GCA GCT ATG GCA ACT GTC C-3', and IL-1β reverse, 5'-GGT CAG ACA GCA CGA GGC-3', which amplifi ed a 420 base pair sequence; COX-2 forward, 5'-GCA AAT CCT TGC TGT TCC AAT C-3', and COX-2 reverse, 5'-GGA GAA GGC TTC CCA GCT TTT G-3', which amplifi ed a 335 base pair sequence, and GAPDH forward, 5'-GCC ATC AAC GAC CCC TTC AT-3', and GAPDH reverse, 5'-CGC CTG CTT CAC CAC CTT CT-3', which amplifi ed a 702 base pair sequence of rat GAPDH. RT-PCR was performed using the MyCycler Thermal Cycler (Bio-Rad Lab., UK) and thermal cycler conditions were as follows: denaturation, annealing, and extension at 98, 55, and 72 o C for 10 sec, 30 sec, and 1 min, respectively, for 30 cycles using Ex Taq (TaKaRa, Shiga, Japan). PCR products were electrophoresed on 1.2% agarose gel containing ethidium bromide and visualized using Gel Doc system (BioRad Lab.).
Statistical analysis
Experimental values were represented as arithmetic mean ± SD. One way ANOVA followed by Dunnett's test was used to determine the statistical signifi cance.
RESULTS
In vitro study
Macrophages induce iNOS when stimulated with LPS. LPS treatment (1 μg/ml) of MH-S cells produced high amounts of NO as well as the proinfl ammatory cytokines, TNF-α and IL-6. After 24 h of incubation, a signifi cant amount of NO was produced (27.9 ± 1.2 μM) over the basal level of 2.7 ± 0.1 μM (n=3). Under this condition, BL reduced NO production in a concentration-dependent manner at 10-100 μg/ml (Fig. 2a) . The IC 50 value was calculated to be 102.5 μg/ml. The reference compound, AMT (NOS inhibitor), potently inhibited NO production (59.3% at 1 μM). BL also reduced TNF-α and IL-6 www.biomolther.org major cells recruited in the later time (24 h) of CGN injection (Tomlinson et al., 1994; Willis et al., 1996) . As expected, the exudate volumes of the pleural cavity increased and the cells in the exudates drastically increased in the 5 h model (acute lung infl ammation) ( Table 1) . Under these conditions, BL (400 mg/kg) administered orally led to a considerable reduction in the exudate volume and blocked the recruitment of infl ammatory cells. Indomethacin (20 mg/kg) used as a reference drug production at the same concentration ranges (Fig. 2b and  2c) , with IC 50 values of 61.7 and 48.4 μg/ml, respectively. To elucidate the inhibitory mechanism of iNOS-induced NO production, Western blotting analysis was carried out. As shown in Fig. 2d , BL clearly inhibited iNOS induction in LPS-treated MH-S cells, indicating that the NO inhibitory activity of BL may be mediated, at least in part, by iNOS down-regulation.
In vivo study
To elucidate the in vivo activity against animal models of lung infl ammation, 5 h and 24 h CGN-induced pleurisy tests were employed. Injection of CGN into the pleural cavity resulted in the development of pleurisy as determined by increased exudate volume and recruitment of infl ammatory cells including neutrophils and macrophages; neutrophils are the major cells recruited in the early time while macrophages are the also inhibited both parameters, showing slightly higher activity than BL. Table 2 shows the results of 24 h CGN-induced pleurisy (subacute lung infl ammation). BL (200-400 mg/kg) reduced the exudate volume and cell numbers in the exudates. Specifically, BL induced a reduction of 37.2 and 35.1% against these two parameters when administered at 400 mg/kg (experiment 1). Prednisolone used as a reference drug strongly reduced the exudate volume and cell numbers, while indomethacin reduced the total cell numbers but increased the exudate volume. In comparison, zileuton (5-LOX inhibitor) showed some inhibitory action at 50 mg/mg when administered orally, showing weaker inhibitory activity than BL (400 mg/kg) (experiment 2).
Bronchitis as an animal model was induced by LPS instillation in rats. When LPS was directly instilled intratracheally, bronchitis characterized by infl ammatory cell infi ltration was produced (Fig. 3a) . Under these conditions, BL (200-400 mg/ kg) signifi cantly reduced cell numbers in BALF (41.2% and 66.7% reduction, respectively). The reference drug, montelukast (30 mg/kg, LT receptor antagonist), also reduced cell numbers (26.9%), but was weaker than BL. Moreover, IL-1β and COX-2 expressed in lung tissue was reduced by BL treatment when measured by RT-PCR analysis (Fig. 3b) . Montelukast weakly reduced IL-1β and COX-2 expression. However, IL-6 and TNF-α genes were not detected in control or LPS instilled lung tissue (data not shown). Upon histological observation, a strong reduction of infl ammatory response in the lung was observed in the BL-treated group (400 mg/kg) as well as the montelukast-treated group (Fig. 3c) . 
DISCUSSION
The present investigation clearly demonstrated that BL possesses signifi cant anti-infl ammatory activity against in vitro and in vivo animal models of lung infl ammation, especially bronchitis. BL showed anti-infl ammatory activity comparable to currently used drugs. This study presents strong scientifi c data supporting the potential for the use of BL to treat human bronchitis.
Several prenylated fl avonoids including papyrifl avonol A and broussochalcone A were successfully isolated from the root barks of B. papyrifera as major constituents (Son et al., 2001) . Among these, papyrifl avonol A is a relatively specifi c 5-LOX inhibitor (Chi et al., 2001b) . Papyrifl avonol A has also been found to inhibit allergic responses in vivo (Kwak et al., 2003) . Because 5-LOX inhibitors have the potential to treat bronchial asthma as well as bronchitis, BL is thought to inhibit lung infl ammation. In addition, broussochalcone A possesses iNOS down-regulating activity (Cheng et al., 2001) . Furthermore, L. japonica is a well-known anti-infl ammatory drug (Lee et al., 1998) . This plant material is widely used to treat respiratory infl ammation in Korea. Iridoids such as loganin have been isolated from these plant materials as major constituents. These compounds have also been reported to show anti-infl ammatory activity (Lee et al., 1995) . All of this background information led us to examine the inhibitory activity of BL against lung infl ammation, and the results of the present investigation demonstrated that BL is effective for the treatment of animal models of lung infl ammation at doses of 200-400 mg/kg.
Our previous study (Jin et al., 2010) showed that BL inhibits 5-LOX and down-regulates iNOS. In the present investigation, in vitro study demonstrated that BL inhibited NO, TNF-α and IL-6 production by alveolar macrophages and that the NO inhibitory action of BL was mediated in part by iNOS downregulation. These results, in combination with the previous fi ndings, may indicate that BL possesses multiple anti-infl ammatory action mechanisms; 5-LOX inhibition, down-regulation of proinfl ammatory enzymes such as iNOS and inhibition of the production of infl ammatory cytokines including TNF-α, IL-1β and IL-6. All these action mechanisms may contribute to the in vivo anti-infl ammatory activity of BL.
One biomarker of infl ammatory response is infl ammationrelated cell recruitment in the affected lesion. Although we did not differentially count the cell types, BL clearly inhibited infi ltration of infl ammatory cells in 5 h and 24 h CGN-induced pleurisy. These results may indicate that BL considerably inhibits lung infl ammation of the pleural cavity, regardless of whether it is in the acute or subacute state. In addition, BL reduced cell numbers of BALF in a model of bronchitis. Since more than 90% of the cells in BALF were shown to be neutrophils (Starcher and Williams, 1989) , BL is believed to reduce neutrophil infi ltration in bronchitis induced by LPS instillation.
In the present investigation, we used indomethacin (COX inhibitor), prednisolone (steroidal anti-infl ammatory drug), zileuton (5-LOX inhibitor) and montelukast (LT receptor antagonist) as the reference drugs depending on the in vivo experiments employed. In acute CGN-pleurisy (5 h), indomethacin strongly inhibited infl ammatory responses based on cell numbers and pleurisy volume. Conversely, indomethacin increased the exudate volume in subacute CGN-pleurisy (24 h), while the 5-LOX inhibitors, zileuton and BL, inhibited this response. These results are well matched with the previous fi ndings that 5-LOX is important to provoke infl ammatory response in CGN-induced pleurisy (Cuzzocrea et al., 2003) and 5-LOX inhibitors are active on this animal model (Batt, 1992) . In contrast, indomethacin inhibits COXs; thus, a considerable amount of arachidonic acid may be converted to LTs by 5-LOX, leading to an increase in the exudate volume in the 24 h model. Montelukast (30 mg/kg) showed inhibitory activity against bronchitis induced by LPS instillation, being less active than BL (400 mg/kg) for blocking cell recruitment. In addition, montelukast clearly inhibited IL-1β and COX-2 m-RNA production and alleviated the lung infl ammation shown by histological observation. These results are well correlated with the fact that LT receptor antagonist is effective for treating allergic asthma and bronchitis (Jeffery, 2001) . When compared with the pharmacological actions of the reference drugs, BL showed broad inhibitory activity against these animal models, pleural cavity infl ammation and bronchitis. Therefore, the results of the present study strongly suggest that BL has the potential for treatment of human lung infl ammation as well as bronchitis.
In conclusion, the phytoformula, BL (mixture of B. papyrifera and L. japonica), showed in vitro and in vivo anti-infl ammatory activity. BL exerted signifi cant inhibitory activity in animal models of lung infl ammation and against bronchitis. Moreover, BL has multiple action mechanisms. Specifi cally, it inhibits 5-LOX, down-regulates proinfl ammatory enzymes such as iNOS and inhibits the production of infl ammatory cytokines such as TNF-α and IL-6. All of these action mechanisms may participate in the in vivo action of BL. Taken together, these fi ndings indicate that BL has the potential for use in the treatment of human bronchitis.
